A once-daily tablet of apalutamide (Erleada) is now available for patients with prostate cancer receiving the androgen receptor inhibitor, accordingto Janssen Pharmaceutical Companies of Johnson & Johnson.1

Patients now have the option of receiving their treatment as one 240-mg tablet or the previously available regimen of four 60-mg tablets.

Apalutamide is approved by the FDA for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC) or metastatic castration-sensitive prostate cancer (mCSPC). These patients now have the option of receiving their treatment as one 240-mg tablet or the previously available regimen of four 60-mg tablets.

“Each person and their cancer are unique and, as such, there is no one-size-fits-all approach to treatment,” Luca Dezzani, MD, vice president, Medical Affairs, Solid Tumor, Janssen Scientific Affairs, LLC, stated in a press release. "The availability of 240-mg and 60-mg strength options of Erleada demonstrates Janssen’s commitment to prostate cancer patients and provides prescribers flexibility in dosing and methods of administration to fit each patient’s unique needs.”

Apalutamide was initially approved by the FDA in 2018 for the treatment of patients with nmCRPC. The approval was based on the phase 3 SPARTAN trial. The data from the trial that the FDA reviewed at the time showed that apalutamide reduced the risk of metastasis or death by 72% in patients with nmCRPC.2 The median metastasis-free survival was 40.5 months in the apalutamide arm versus 16.2 months in the placebo arm (HR, 0.28; P